Get started Log in

2696 — Shanghai Henlius Biotech News Story

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapNeutral

Market Cap
HK$35.72bn
Enterprise Value
HK$39.39bn
Revenue
CNY6.67bn

Brief: Fosun Pharma Says Henlius Biotech's Pertuzumab Injection Approved By China Regulator

Shanghai Henlius Biotech

29/05/2026 11:03

BRIEF-Fosun Pharma Says Henlius Biotech's Pertuzumab Injection Approved By China RegulatorMay 29 (Reuters) - Fosun Pharma 600196.SS:
SAYS UNIT HENLIUS BIOTECH'S PERTUZUMAB INJECTION APPLICATION APPROVED BY CHINA REGULATOR
Source text
Further company coverage: 600196.SS

 (Reporting by Beijing Newsroom)
 ((Ethan.Wang@thomsonreuters.com;))

Recent news on Shanghai Henlius Biotech

Brief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
30/09/2026 11:25
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
23/09/2026 11:28
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
11/09/2026 11:26
China's Henlius H1 revenue jumps on drug sales, license income
21/08/2026 12:36
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln
21/08/2026 12:27